Amarin Corporation Plc (AMRN) 2.33 $AMRN
Stock Updates on Biotech -- Celgene, Amgen, PDL BioPharma, Amarin, and Pharmacyclics
PR Newswire - Tue Apr 21, 7:30AM CDT
Editor Note: For more information about this release, please scroll to bottom.
PCYC: 256.59 (-0.51), AMRN: 2.33 (-0.10), AMGN: 167.91 (-1.26), PDLI: 7.02 (-0.09), CELG: 118.71 (+2.62), CELGZ: 2.76 (-0.12)
Amarin: Vascepa Growth Moderates, But Long-Term Liquidity Still Appears Fine
Elephant Analytics - at Seeking Alpha - Sun Apr 19, 1:31AM CDT
AMRN: 2.33 (-0.10)
With Shares Down But Prescriptions Up, It's Time To Accumulate Amarin
Clinically Sound Investor - at Seeking Alpha - Fri Apr 17, 12:47PM CDT
AMRN: 2.33 (-0.10)
Amarin's Constellation Of Possibilities Defy The Fall Of Night
Scrying Biotech - at Seeking Alpha - Mon Apr 13, 1:04PM CDT
AMRN: 2.33 (-0.10)
How Amarin Corporation (AMRN) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 09, 7:55AM CDT
Amarin Corporation is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
AMRN: 2.33 (-0.10)
Healthcare stock screen of the month: Price extended, poor fundamentals
Seeking Alpha - at Seeking Alpha - Wed Apr 08, 12:05PM CDT
CRMD: 8.61 (-0.22), ADXS: 23.34 (-0.27), CYTX: 0.99 (+0.01), CNDO: 3.97 (-0.14), AMRN: 2.33 (-0.10), AVEO: 1.92 (-0.08), NVGN: 6.54 (-0.01), AXN: 1.71 (+0.02), NYMX: 1.39 (-0.05), DRRX: 2.11 (-0.46), RIGL: 4.88 (+0.55), CAPN: 6.87 (+0.01)
Amarin and Non-Profit, Walk with a Doc Partner to Expand National Health Awareness Efforts
Marketwired - Wed Apr 08, 7:01AM CDT
Amarin Corporation, plc (NASDAQ: AMRN) and Walk with a Doc, a national nonprofit organization, today announced a 2015 partnership to expand the reach of their national health awareness efforts.
AMRN: 2.33 (-0.10)
Here's the Lowdown on Amarin Corporation PLCs 55% Move Higher in March
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 07, 8:19AM CDT
What: Shares of Amarin (NASDAQ: AMRN), a small-cap biopharmaceutical company focused on developing drugs designed to treat cardiovascular diseases, skyrocketed 55% in March, according to data from S&P Capital IQ , after reporting...
AMRN: 2.33 (-0.10)
Amarin: Vascepa To Continue Steady Growth
Clinically Sound Investor - at Seeking Alpha - Mon Apr 06, 3:45PM CDT
AMRN: 2.33 (-0.10)
3 Biotech Stocks in Danger of Running Out of Cash
Sean Williams, Brian Orelli, and George Budwell, The Motley Fool - Motley Fool - Thu Apr 02, 11:45AM CDT
Source: Flickr user Mike Poresky Few sectors offer a greater potential for risk and reward than biotechnology. It's a sector where many companies are still in the early stages of their drug development process, but if you happen to catch a winner...
AMRN: 2.33 (-0.10), GALE: 1.45 (+0.02), EXEL: 3.08 (-0.02)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 4:36PM CDT
VUG: 110.21 (+0.17), CRS: 41.83 (+0.05), BCRX: 10.35 (-0.18), UTIW: 9.27 (-0.14), ENZ: 3.01 (-0.02), AMRN: 2.33 (-0.10), NMBL: 24.38 (-0.28), TAHO: 11.88 (+0.05), EIX: 61.58 (+1.14), DYAX: 27.44 (-0.85)
Amarin: A Look At The Recent Selloff And Negative Perceptions
Clinically Sound Investor - at Seeking Alpha - Tue Mar 31, 9:42AM CDT
AMRN: 2.33 (-0.10)
Should Investors Toss in the Towel on Amarin Corp Plc?
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Thu Mar 26, 11:02AM CDT
Investing in biotech is a risky business, and investing in emerging clinical stage companies doubly so. Many investors have jumped on the enticing bandwagon of the next blockbuster drug, only to have their hopes dashed before the promise is...
PFE: 35.27 (-0.09), AMRN: 2.33 (-0.10)
Shake Shack Shares Persist On The Hard To Borrow List
Interactive Brokers - Seeking Alpha - Tue Mar 24, 1:57AM CDT
Demand for shares of Shake Shack (NYSE: SHAK ) has been consistent during the past two weeks. Much of the demand was ignited roughly two weeks ago following the release of SHAK's fourth-quarter earnings, which the market initially had a hard time...
HLF: 41.10 (-3.75), TSLA: 218.43 (-0.17), SHAK: 68.53 (+5.80), MVIS: 3.68 (+0.12), AMRN: 2.33 (-0.10), CLF: 6.03 (+0.47), AXN: 1.71 (+0.02), NVGN: 6.54 (-0.01), AMPE: 2.73 (-0.16), FXCM: 2.08 (-0.03), RIG: 16.40 (-0.57), CNDO: 3.97 (-0.14), CEN: 16.71 (-0.39)
Biotech Stocks: 2 to Avoid, 1 to Buy
Todd Campbell, The Motley Fool - Motley Fool - Sun Mar 22, 11:56AM CDT
Source: Celgene Corp. Biotech stocks can swing wildly based on drugs in develoment and clinical trial data, and that means the industry is among the riskiest for investors. Figuring out which biotechs are too risky to buy is just as important as...
OREX: 7.36 (-0.08), AMRN: 2.33 (-0.10), VVUS: 2.46 (-0.04), ARNA: 4.49 (+0.05), CELG: 118.71 (+2.62)
Amarin's Case Vs. FDA Will Garner Positive Attention
Clinically Sound Investor - at Seeking Alpha - Fri Mar 20, 4:44PM CDT
AMRN: 2.33 (-0.10)
Amarin Argues In Court For Vascepa Exclusivity
Curve Tech Investing - at Seeking Alpha - Wed Mar 18, 7:39PM CDT
AMRN: 2.33 (-0.10), GSK: 46.59 (+0.28)
Hot Stock: Amarin, Shares Gain 9.7% (AMRN)
Comtex SmarTrend(R) - Wed Mar 18, 10:37AM CDT
Amarin (NASDAQ:AMRN) is one of today's best performing low-priced stocks, up 9.7% to $2.60 on 2.6x average daily volume. Thus far today, Amarin has traded 12.1 million shares, vs. average volume of 4.7 million shares per day. The stock has outperformed the Dow (9.7% to the Dow's -0.3%) and outperformed the S&P 500 (9.7% to the S&P's -0.2%) during today's trading.
AMRN: 2.33 (-0.10)
Biotech Stocks Technical Study -- Orexigen Therapeutics, Celgene, PDL BioPharma, Amarin, and Synergy Pharma
PR Newswire - Wed Mar 18, 7:55AM CDT
Editor Note: For more information about this release, please scroll to bottom.
SGYP: 4.01 (-0.10), OREX: 7.36 (-0.08), AMRN: 2.33 (-0.10), PDLI: 7.02 (-0.09), CELG: 118.71 (+2.62), CELGZ: 2.76 (-0.12)
Stock Updates on Biotech -- Celgene, Amgen, PDL BioPharma, Amarin, and Pharmacyclics
PR Newswire - Tue Apr 21, 7:30AM CDT
Editor Note: For more information about this release, please scroll to bottom.
PCYC: 256.59 (-0.51), AMRN: 2.33 (-0.10), AMGN: 167.91 (-1.26), PDLI: 7.02 (-0.09), CELG: 118.71 (+2.62), CELGZ: 2.76 (-0.12)
Amarin: Vascepa Growth Moderates, But Long-Term Liquidity Still Appears Fine
Elephant Analytics - at Seeking Alpha - Sun Apr 19, 1:31AM CDT
AMRN: 2.33 (-0.10)
With Shares Down But Prescriptions Up, It's Time To Accumulate Amarin
Clinically Sound Investor - at Seeking Alpha - Fri Apr 17, 12:47PM CDT
AMRN: 2.33 (-0.10)
Amarin's Constellation Of Possibilities Defy The Fall Of Night
Scrying Biotech - at Seeking Alpha - Mon Apr 13, 1:04PM CDT
AMRN: 2.33 (-0.10)
How Amarin Corporation (AMRN) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 09, 7:55AM CDT
Amarin Corporation is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
AMRN: 2.33 (-0.10)
Healthcare stock screen of the month: Price extended, poor fundamentals
Seeking Alpha - at Seeking Alpha - Wed Apr 08, 12:05PM CDT
CRMD: 8.61 (-0.22), ADXS: 23.34 (-0.27), CYTX: 0.99 (+0.01), CNDO: 3.97 (-0.14), AMRN: 2.33 (-0.10), AVEO: 1.92 (-0.08), NVGN: 6.54 (-0.01), AXN: 1.71 (+0.02), NYMX: 1.39 (-0.05), DRRX: 2.11 (-0.46), RIGL: 4.88 (+0.55), CAPN: 6.87 (+0.01)
Amarin and Non-Profit, Walk with a Doc Partner to Expand National Health Awareness Efforts
Marketwired - Wed Apr 08, 7:01AM CDT
Amarin Corporation, plc (NASDAQ: AMRN) and Walk with a Doc, a national nonprofit organization, today announced a 2015 partnership to expand the reach of their national health awareness efforts.
AMRN: 2.33 (-0.10)
Here's the Lowdown on Amarin Corporation PLCs 55% Move Higher in March
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 07, 8:19AM CDT
What: Shares of Amarin (NASDAQ: AMRN), a small-cap biopharmaceutical company focused on developing drugs designed to treat cardiovascular diseases, skyrocketed 55% in March, according to data from S&P Capital IQ , after reporting...
AMRN: 2.33 (-0.10)
Amarin: Vascepa To Continue Steady Growth
Clinically Sound Investor - at Seeking Alpha - Mon Apr 06, 3:45PM CDT
AMRN: 2.33 (-0.10)
3 Biotech Stocks in Danger of Running Out of Cash
Sean Williams, Brian Orelli, and George Budwell, The Motley Fool - Motley Fool - Thu Apr 02, 11:45AM CDT
Source: Flickr user Mike Poresky Few sectors offer a greater potential for risk and reward than biotechnology. It's a sector where many companies are still in the early stages of their drug development process, but if you happen to catch a winner...
AMRN: 2.33 (-0.10), GALE: 1.45 (+0.02), EXEL: 3.08 (-0.02)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 4:36PM CDT
VUG: 110.21 (+0.17), CRS: 41.83 (+0.05), BCRX: 10.35 (-0.18), UTIW: 9.27 (-0.14), ENZ: 3.01 (-0.02), AMRN: 2.33 (-0.10), NMBL: 24.38 (-0.28), TAHO: 11.88 (+0.05), EIX: 61.58 (+1.14), DYAX: 27.44 (-0.85)
Amarin: A Look At The Recent Selloff And Negative Perceptions
Clinically Sound Investor - at Seeking Alpha - Tue Mar 31, 9:42AM CDT
AMRN: 2.33 (-0.10)
Should Investors Toss in the Towel on Amarin Corp Plc?
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Thu Mar 26, 11:02AM CDT
Investing in biotech is a risky business, and investing in emerging clinical stage companies doubly so. Many investors have jumped on the enticing bandwagon of the next blockbuster drug, only to have their hopes dashed before the promise is...
PFE: 35.27 (-0.09), AMRN: 2.33 (-0.10)
Shake Shack Shares Persist On The Hard To Borrow List
Interactive Brokers - Seeking Alpha - Tue Mar 24, 1:57AM CDT
Demand for shares of Shake Shack (NYSE: SHAK ) has been consistent during the past two weeks. Much of the demand was ignited roughly two weeks ago following the release of SHAK's fourth-quarter earnings, which the market initially had a hard time...
HLF: 41.10 (-3.75), TSLA: 218.43 (-0.17), SHAK: 68.53 (+5.80), MVIS: 3.68 (+0.12), AMRN: 2.33 (-0.10), CLF: 6.03 (+0.47), AXN: 1.71 (+0.02), NVGN: 6.54 (-0.01), AMPE: 2.73 (-0.16), FXCM: 2.08 (-0.03), RIG: 16.40 (-0.57), CNDO: 3.97 (-0.14), CEN: 16.71 (-0.39)
Biotech Stocks: 2 to Avoid, 1 to Buy
Todd Campbell, The Motley Fool - Motley Fool - Sun Mar 22, 11:56AM CDT
Source: Celgene Corp. Biotech stocks can swing wildly based on drugs in develoment and clinical trial data, and that means the industry is among the riskiest for investors. Figuring out which biotechs are too risky to buy is just as important as...
OREX: 7.36 (-0.08), AMRN: 2.33 (-0.10), VVUS: 2.46 (-0.04), ARNA: 4.49 (+0.05), CELG: 118.71 (+2.62)
Amarin's Case Vs. FDA Will Garner Positive Attention
Clinically Sound Investor - at Seeking Alpha - Fri Mar 20, 4:44PM CDT
AMRN: 2.33 (-0.10)
Amarin Argues In Court For Vascepa Exclusivity
Curve Tech Investing - at Seeking Alpha - Wed Mar 18, 7:39PM CDT
AMRN: 2.33 (-0.10), GSK: 46.59 (+0.28)
Hot Stock: Amarin, Shares Gain 9.7% (AMRN)
Comtex SmarTrend(R) - Wed Mar 18, 10:37AM CDT
Amarin (NASDAQ:AMRN) is one of today's best performing low-priced stocks, up 9.7% to $2.60 on 2.6x average daily volume. Thus far today, Amarin has traded 12.1 million shares, vs. average volume of 4.7 million shares per day. The stock has outperformed the Dow (9.7% to the Dow's -0.3%) and outperformed the S&P 500 (9.7% to the S&P's -0.2%) during today's trading.
AMRN: 2.33 (-0.10)
Biotech Stocks Technical Study -- Orexigen Therapeutics, Celgene, PDL BioPharma, Amarin, and Synergy Pharma
PR Newswire - Wed Mar 18, 7:55AM CDT
Editor Note: For more information about this release, please scroll to bottom.
SGYP: 4.01 (-0.10), OREX: 7.36 (-0.08), AMRN: 2.33 (-0.10), PDLI: 7.02 (-0.09), CELG: 118.71 (+2.62), CELGZ: 2.76 (-0.12)
